You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAtomoxetine
Accession NumberDB00289  (APRD00614)
TypeSmall Molecule
GroupsApproved
DescriptionAtomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]
Structure
Thumb
Synonyms
(-)-Tomoxetine
Tomoxetina
Tomoxetine
Tomoxetinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AtomoxetineCapsule25 mgOralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
AtomoxetineCapsule18 mgOralPro Doc Limitee2012-11-29Not applicableCanada
AtomoxetineCapsule40 mgOralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
AtomoxetineCapsule25 mgOralPro Doc Limitee2012-11-29Not applicableCanada
AtomoxetineCapsule10 mgOralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
AtomoxetineCapsule60 mgOralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
AtomoxetineCapsule40 mgOralPro Doc Limitee2012-11-29Not applicableCanada
AtomoxetineCapsule18 mgOralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
AtomoxetineCapsule60 mgOralPro Doc Limitee2012-11-29Not applicableCanada
AtomoxetineCapsule10 mgOralPro Doc Limitee2012-11-29Not applicableCanada
Dom-atomoxetineCapsule25 mgOralDominion Pharmacal2013-04-23Not applicableCanada
Dom-atomoxetineCapsule40 mgOralDominion Pharmacal2013-04-23Not applicableCanada
Dom-atomoxetineCapsule10 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-atomoxetineCapsule60 mgOralDominion Pharmacal2013-05-22Not applicableCanada
Dom-atomoxetineCapsule18 mgOralDominion PharmacalNot applicableNot applicableCanada
Mylan-atomoxetineCapsule60 mgOralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetineCapsule18 mgOralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetineCapsule80 mgOralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetineCapsule25 mgOralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetineCapsule100 mgOralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetineCapsule40 mgOralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
PMS-atomoxetineCapsule18 mgOralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetineCapsule80 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-atomoxetineCapsule25 mgOralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetineCapsule100 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-atomoxetineCapsule40 mgOralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetineCapsule60 mgOralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetineCapsule10 mgOralPharmascience Inc2012-06-13Not applicableCanada
Ratio-atomoxetineCapsule10 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetineCapsule60 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetineCapsule18 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetineCapsule25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetineCapsule40 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Riva-atomoxetineCapsule40 mgOralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetineCapsule10 mgOralLaboratoire Riva Inc2013-07-18Not applicableCanada
Riva-atomoxetineCapsule60 mgOralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetineCapsule18 mgOralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetineCapsule80 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-atomoxetineCapsule25 mgOralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetineCapsule100 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz AtomoxetineCapsule40 mgOralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz AtomoxetineCapsule10 mgOralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz AtomoxetineCapsule60 mgOralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz AtomoxetineCapsule18 mgOralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz AtomoxetineCapsule80 mgOralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz AtomoxetineCapsule25 mgOralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz AtomoxetineCapsule100 mgOralSandoz Canada Incorporated2012-05-30Not applicableCanada
StratteraCapsule25 mg/1OralAvera Mc Kennan Hospital2015-03-05Not applicableUs
StratteraKitOralEli Lilly and Company2014-08-31Not applicableUs
StratteraCapsule25 mg/1OralTYA Pharmaceuticals2003-01-10Not applicableUs
StratteraCapsule100 mgOralEli Lilly Canada Inc2010-01-08Not applicableCanada
StratteraCapsule10 mg/1OralEli Lilly and Company2003-01-10Not applicableUs
StratteraCapsule40 mg/1OralREMEDYREPACK INC.2013-05-092016-10-13Us
StratteraCapsule25 mgOralEli Lilly Canada Inc2005-03-03Not applicableCanada
StratteraCapsule40 mg/1OralCarilion Materials Management2003-01-10Not applicableUs
StratteraCapsule60 mg/1OralEli Lilly and Company2003-01-10Not applicableUs
StratteraCapsule40 mg/1OralAvera Mc Kennan Hospital2015-03-23Not applicableUs
StratteraKitOralEli Lilly and Company2014-08-31Not applicableUs
StratteraCapsule10 mg/1OralCarilion Materials Management2003-01-10Not applicableUs
StratteraCapsule25 mg/1OralEli Lilly and Company2003-01-10Not applicableUs
StratteraCapsule40 mgOralEli Lilly Canada Inc2005-03-03Not applicableCanada
StratteraCapsule18 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-13Not applicableUs
StratteraCapsule60 mg/1OralCarilion Materials Management2003-01-10Not applicableUs
StratteraCapsule80 mg/1OralEli Lilly and Company2006-03-01Not applicableUs
StratteraKitOralEli Lilly and Company2014-08-31Not applicableUs
StratteraCapsule10 mgOralEli Lilly Canada Inc2005-02-24Not applicableCanada
StratteraCapsule40 mg/1OralEli Lilly and Company2003-01-10Not applicableUs
StratteraCapsule18 mg/1OralCarilion Materials Management2003-01-10Not applicableUs
StratteraCapsule60 mgOralEli Lilly Canada Inc2005-03-03Not applicableCanada
StratteraCapsule25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-13Not applicableUs
StratteraCapsule10 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
StratteraCapsule100 mg/1OralEli Lilly and Company2006-03-01Not applicableUs
StratteraCapsule80 mg/1OralREMEDYREPACK INC.2011-12-222017-11-16Us
StratteraCapsule10 mg/1OralSTAT Rx USA LLC2009-03-16Not applicableUs
StratteraCapsule18 mgOralEli Lilly Canada Inc2005-02-24Not applicableCanada
StratteraCapsule18 mg/1OralEli Lilly and Company2003-01-10Not applicableUs
StratteraCapsule25 mg/1OralCarilion Materials Management2003-01-10Not applicableUs
StratteraCapsule80 mgOralEli Lilly Canada Inc2009-12-16Not applicableCanada
StratteraCapsule40 mg/1OralCardinal Health2003-01-10Not applicableUs
Teva-atomoxetineCapsule100 mgOralTeva Canada Limited2013-10-15Not applicableCanada
Teva-atomoxetineCapsule40 mgOralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetineCapsule10 mgOralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetineCapsule60 mgOralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetineCapsule18 mgOralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetineCapsule80 mgOralTeva Canada Limited2014-02-28Not applicableCanada
Teva-atomoxetineCapsule25 mgOralTeva Canada Limited2010-09-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-atomoxetineCapsule18 mgOralApotex Inc2011-03-15Not applicableCanada
Apo-atomoxetineCapsule80 mgOralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetineCapsule25 mgOralApotex Inc2011-03-15Not applicableCanada
Apo-atomoxetineCapsule100 mgOralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetineCapsule40 mgOralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetineCapsule60 mgOralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetineCapsule10 mgOralApotex Inc2011-03-15Not applicableCanada
Atomoxetine HydrochlorideCapsule10 mg/1OralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine HydrochlorideCapsule10 mg/1OralSandoz Inc2010-12-15Not applicableUs
Atomoxetine HydrochlorideCapsule60 mg/1OralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine HydrochlorideCapsule60 mg/1OralSandoz Inc2010-12-15Not applicableUs
Atomoxetine HydrochlorideCapsule18 mg/1OralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine HydrochlorideCapsule18 mg/1OralSandoz Inc2010-12-15Not applicableUs
Atomoxetine HydrochlorideCapsule80 mg/1OralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine HydrochlorideCapsule80 mg/1OralSandoz Inc2010-12-15Not applicableUs
Atomoxetine HydrochlorideCapsule25 mg/1OralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine HydrochlorideCapsule25 mg/1OralSandoz Inc2010-12-15Not applicableUs
Atomoxetine HydrochlorideCapsule100 mg/1OralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine HydrochlorideCapsule100 mg/1OralSandoz Inc2010-12-15Not applicableUs
Atomoxetine HydrochlorideCapsule40 mg/1OralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine HydrochlorideCapsule40 mg/1OralSandoz Inc2010-12-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AttentinNot Available
TomoxetinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Atomoxetine hydrochloride
82248-59-7
Thumb
  • InChI Key: LUCXVPAZUDVVBT-UNTBIKODSA-N
  • Monoisotopic Mass: 291.138992
  • Average Mass: 291.82
DBSALT001207
Categories
UNIIASW034S0B8
CAS number83015-26-3
WeightAverage: 255.3547
Monoisotopic: 255.162314299
Chemical FormulaC17H21NO
InChI KeyVHGCDTVCOLNTBX-QGZVFWFLSA-N
InChI
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
IUPAC Name
methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine
SMILES
CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.
Structured Indications
PharmacodynamicsAtomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). Atomoxetine is classified as a norepinephrine reuptake inhibitor, and is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under six years old. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants, is not scheduled as a controlled substance and has proven in clinical trials to offer 24 hour coverage of symptoms associated with ADHD in adults and children.
Mechanism of actionThe precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined through in-vitro studies. Atomoxetine appears to have minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinyesNot AvailableHumanP23975 details
Sodium-dependent serotonin transporterProteinunknownNot AvailableHumanP31645 details
Sodium-dependent dopamine transporterProteinunknown
binder
HumanQ01959 details
NMDA receptorProtein groupunknown
blocker
Humannot applicabledetails
Related Articles
AbsorptionAtomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) have no effect on atomoxetine bioavailability. Absorption is minimally affected by food.
Volume of distribution
  • 0.85 L/kg
Protein bindingAt therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin.
Metabolism

Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs).

SubstrateEnzymesProduct
Atomoxetine
Not Available
4-hydroxyatomoxetineDetails
Route of eliminationNot Available
Half life5 hours
Clearance
  • 0.35 L/hr/kg [after oral administration in adult extensive metabolizers]
  • 0.03 L/hr/kg [administration of atomoxetine to poor metabolizers]
ToxicityThe most commonly reported symptoms accompanying acute and chronic overdoses are somnolence, agitation, hyperactivity, abnormal behavior, and gastrointestinal symptoms.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Atomoxetine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the central neurotoxic activities of Atomoxetine.Experimental
AbirateroneThe serum concentration of Atomoxetine can be increased when it is combined with Abiraterone.Approved
AcebutololAtomoxetine may increase the hypertensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Atomoxetine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Atomoxetine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Atomoxetine.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Atomoxetine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Atomoxetine.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Atomoxetine.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Atomoxetine.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Atomoxetine.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Atomoxetine.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Atomoxetine.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Atomoxetine.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Atomoxetine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Atomoxetine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Atomoxetine.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Atomoxetine.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Atomoxetine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Atomoxetine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Atomoxetine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Atomoxetine.Approved
AmiodaroneThe serum concentration of Atomoxetine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Atomoxetine.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Atomoxetine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Atomoxetine.Approved
AmphetamineAtomoxetine may increase the hypertensive activities of Amphetamine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Atomoxetine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Atomoxetine.Approved
AnagrelideAtomoxetine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Atomoxetine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Atomoxetine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Atomoxetine.Approved, Investigational
AprepitantThe metabolism of Aprepitant can be decreased when combined with Atomoxetine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Atomoxetine.Approved
ArbutamineAtomoxetine may increase the tachycardic activities of Arbutamine.Approved
ArformoterolAtomoxetine may increase the tachycardic activities of Arformoterol.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Atomoxetine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.Approved, Investigational
ArmodafinilThe metabolism of Atomoxetine can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideAtomoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherAtomoxetine may increase the QTc-prolonging activities of Artemether.Approved
AsenapineAtomoxetine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Atomoxetine.Approved, Withdrawn
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Atomoxetine.Approved, Investigational
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Atomoxetine.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Atomoxetine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Atomoxetine.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Atomoxetine.Approved
AzithromycinAtomoxetine may increase the QTc-prolonging activities of Azithromycin.Approved
BambuterolAtomoxetine may increase the tachycardic activities of Bambuterol.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Atomoxetine.Investigational
BedaquilineAtomoxetine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenmoxinBenmoxin may increase the central neurotoxic activities of Atomoxetine.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Atomoxetine.Approved
BenzphetamineAtomoxetine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Atomoxetine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Atomoxetine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Atomoxetine.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Atomoxetine.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Atomoxetine.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Atomoxetine.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Atomoxetine.Approved
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Atomoxetine.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Atomoxetine.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Atomoxetine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atomoxetine.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Atomoxetine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Atomoxetine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Atomoxetine.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Atomoxetine.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Atomoxetine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Atomoxetine.Approved
BucindololAtomoxetine may increase the hypertensive activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Atomoxetine.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Atomoxetine.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Atomoxetine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Atomoxetine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Atomoxetine can be increased when it is combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Atomoxetine.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Atomoxetine.Approved, Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Atomoxetine.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Atomoxetine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Atomoxetine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Atomoxetine.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Atomoxetine.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Atomoxetine.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Atomoxetine.Approved
CarbamazepineThe metabolism of Atomoxetine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Atomoxetine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Atomoxetine.Approved
CaroxazoneCaroxazone may increase the central neurotoxic activities of Atomoxetine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Atomoxetine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Atomoxetine.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Atomoxetine.Approved, Investigational
CeliprololAtomoxetine may increase the hypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Atomoxetine.Approved, Vet Approved
CeritinibAtomoxetine may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Atomoxetine.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Atomoxetine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Atomoxetine.Approved
ChloramphenicolThe metabolism of Atomoxetine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Atomoxetine.Approved, Illicit
ChloroquineAtomoxetine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Atomoxetine.Approved
ChlorphentermineAtomoxetine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineAtomoxetine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Atomoxetine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Atomoxetine.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Atomoxetine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Atomoxetine.Approved
CimetidineThe metabolism of Atomoxetine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Atomoxetine can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Atomoxetine.Approved
CiprofloxacinAtomoxetine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideAtomoxetine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramAtomoxetine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinAtomoxetine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Atomoxetine can be decreased when combined with Clemastine.Approved
ClenbuterolAtomoxetine may increase the hypertensive activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Atomoxetine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Atomoxetine.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Atomoxetine.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Atomoxetine.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Atomoxetine.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Atomoxetine.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Atomoxetine.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Atomoxetine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Atomoxetine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Atomoxetine.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Atomoxetine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Atomoxetine.Approved, Illicit
ClotrimazoleThe metabolism of Atomoxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineAtomoxetine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Atomoxetine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Atomoxetine.Approved
CocaineThe serum concentration of Atomoxetine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Atomoxetine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Atomoxetine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Atomoxetine.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Atomoxetine.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Atomoxetine.Approved
CrizotinibAtomoxetine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Atomoxetine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Atomoxetine.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Atomoxetine.Approved, Investigational
DabrafenibThe serum concentration of Atomoxetine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Atomoxetine.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Atomoxetine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Atomoxetine.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Atomoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Atomoxetine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Atomoxetine.Approved, Investigational
DarunavirThe serum concentration of Atomoxetine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Atomoxetine.Approved
DasatinibThe metabolism of Dasatinib can be decreased when combined with Atomoxetine.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Atomoxetine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Atomoxetine.Approved
DelavirdineThe serum concentration of Atomoxetine can be increased when it is combined with Delavirdine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Atomoxetine.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Atomoxetine.Approved
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Atomoxetine.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Atomoxetine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Atomoxetine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Atomoxetine.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Atomoxetine.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Atomoxetine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Atomoxetine.Approved, Vet Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Atomoxetine.Approved
DigoxinThe metabolism of Digoxin can be decreased when combined with Atomoxetine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Atomoxetine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Atomoxetine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Atomoxetine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Atomoxetine.Approved
DipivefrinAtomoxetine may increase the tachycardic activities of Dipivefrin.Approved
DisopyramideAtomoxetine may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Atomoxetine.Approved
DobutamineAtomoxetine may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Atomoxetine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Atomoxetine.Approved
DolasetronAtomoxetine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Atomoxetine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Atomoxetine.Approved
DopamineAtomoxetine may increase the hypertensive activities of Dopamine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Atomoxetine.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Atomoxetine.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Atomoxetine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atomoxetine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Atomoxetine.Approved, Investigational
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Atomoxetine.Approved, Illicit
DronedaroneAtomoxetine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolAtomoxetine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DroxidopaAtomoxetine may increase the tachycardic activities of Droxidopa.Approved, Investigational
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Atomoxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Atomoxetine.Approved, Investigational
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Atomoxetine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Atomoxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Atomoxetine.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Atomoxetine.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Atomoxetine.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Atomoxetine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Atomoxetine.Investigational
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Atomoxetine.Approved
EphedraAtomoxetine may increase the tachycardic activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineAtomoxetine may increase the hypertensive activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Atomoxetine.Approved, Investigational
EpinephrineAtomoxetine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Atomoxetine.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Atomoxetine.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Atomoxetine.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Atomoxetine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Atomoxetine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Atomoxetine.Approved, Investigational
ErythromycinAtomoxetine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramAtomoxetine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Atomoxetine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Atomoxetine.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Atomoxetine.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Atomoxetine.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Atomoxetine.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Atomoxetine.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Atomoxetine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Atomoxetine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Atomoxetine.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Atomoxetine.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Atomoxetine.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Atomoxetine.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Atomoxetine.Approved, Illicit
EtilefrineAtomoxetine may increase the hypertensive activities of Etilefrine.Withdrawn
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Atomoxetine.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Atomoxetine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Atomoxetine.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Atomoxetine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Atomoxetine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Atomoxetine.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Atomoxetine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Atomoxetine.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Atomoxetine.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Atomoxetine.Approved
FenoterolAtomoxetine may increase the hypertensive activities of Fenoterol.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Atomoxetine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atomoxetine.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Atomoxetine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Atomoxetine.Approved, Investigational
FlecainideAtomoxetine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Atomoxetine.Approved
FluconazoleThe metabolism of Atomoxetine can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Atomoxetine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Atomoxetine.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Atomoxetine.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Atomoxetine.Approved
FluoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolAtomoxetine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Atomoxetine.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Atomoxetine.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Atomoxetine.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Atomoxetine.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Atomoxetine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Atomoxetine.Approved
FluvoxamineThe metabolism of Atomoxetine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolAtomoxetine may increase the tachycardic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Atomoxetine.Approved
FosphenytoinThe metabolism of Atomoxetine can be increased when combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Atomoxetine.Approved, Investigational
FurazolidoneFurazolidone may increase the central neurotoxic activities of Atomoxetine.Approved, Vet Approved
Gadobenic acidAtomoxetine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Atomoxetine.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Atomoxetine.Approved, Investigational
GemfibrozilThe metabolism of Atomoxetine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinAtomoxetine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlipizideThe metabolism of Glipizide can be decreased when combined with Atomoxetine.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Atomoxetine.Approved
GoserelinAtomoxetine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronAtomoxetine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Atomoxetine.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Atomoxetine.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Atomoxetine.Approved
HaloperidolAtomoxetine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Atomoxetine.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Atomoxetine.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Atomoxetine.Approved
HydracarbazineHydracarbazine may increase the central neurotoxic activities of Atomoxetine.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Atomoxetine.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Atomoxetine.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Atomoxetine.Approved, Illicit
Hydroxyamphetamine hydrobromideAtomoxetine may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Atomoxetine.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Atomoxetine.Approved
IbutilideAtomoxetine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Atomoxetine.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Atomoxetine resulting in a loss in efficacy.Approved
IloperidoneAtomoxetine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Atomoxetine.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Atomoxetine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Atomoxetine.Approved, Investigational
IndacaterolAtomoxetine may increase the tachycardic activities of Indacaterol.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Atomoxetine.Approved
IndinavirThe metabolism of Indinavir can be decreased when combined with Atomoxetine.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Atomoxetine.Approved
IproclozideIproclozide may increase the central neurotoxic activities of Atomoxetine.Withdrawn
IproniazidIproniazid may increase the central neurotoxic activities of Atomoxetine.Withdrawn
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Atomoxetine.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Atomoxetine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the central neurotoxic activities of Atomoxetine.Approved
IsoetarineAtomoxetine may increase the tachycardic activities of Isoetarine.Approved
IsoniazidThe metabolism of Atomoxetine can be decreased when combined with Isoniazid.Approved
IsoprenalineAtomoxetine may increase the hypertensive activities of Isoprenaline.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atomoxetine.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atomoxetine.Approved
IsoxsuprineAtomoxetine may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Isradipine can be decreased when combined with Atomoxetine.Approved
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Atomoxetine.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Atomoxetine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Atomoxetine.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Atomoxetine.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Atomoxetine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Atomoxetine.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Atomoxetine.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Atomoxetine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Atomoxetine.Approved
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Atomoxetine.Approved, Investigational
LabetalolAtomoxetine may increase the hypertensive activities of Labetalol.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Atomoxetine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Atomoxetine.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Atomoxetine.Investigational
LenvatinibAtomoxetine may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Atomoxetine.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Atomoxetine.Approved, Investigational
LeuprolideAtomoxetine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Atomoxetine.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Atomoxetine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Atomoxetine.Approved
LevofloxacinAtomoxetine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Atomoxetine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Atomoxetine.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Atomoxetine.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Atomoxetine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Atomoxetine.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Atomoxetine.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Atomoxetine.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Atomoxetine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Atomoxetine.Approved
LopinavirThe serum concentration of Atomoxetine can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Atomoxetine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Atomoxetine.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Atomoxetine.Approved
LovastatinThe metabolism of Lovastatin can be decreased when combined with Atomoxetine.Approved, Investigational
LuliconazoleThe serum concentration of Atomoxetine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Atomoxetine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineAtomoxetine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Atomoxetine.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Atomoxetine.Approved
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Atomoxetine.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Atomoxetine.Approved, Investigational
MebanazineMebanazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Atomoxetine.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Atomoxetine.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Atomoxetine.Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Atomoxetine.Approved, Vet Approved
MephentermineAtomoxetine may increase the hypertensive activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Atomoxetine.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Atomoxetine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Atomoxetine.Approved
MetaraminolAtomoxetine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneAtomoxetine may increase the QTc-prolonging activities of Methadone.Approved
MethamphetamineAtomoxetine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Atomoxetine.Illicit, Withdrawn
MethotrimeprazineThe serum concentration of Atomoxetine can be increased when it is combined with Methotrimeprazine.Approved
MethoxamineAtomoxetine may increase the hypertensive activities of Methoxamine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Atomoxetine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Atomoxetine.Approved, Vet Approved
Methylene blueMethylene blue may increase the central neurotoxic activities of Atomoxetine.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Atomoxetine.Approved, Investigational
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Atomoxetine.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Atomoxetine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Atomoxetine.Approved, Illicit, Withdrawn
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Atomoxetine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Atomoxetine.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Atomoxetine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Atomoxetine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Atomoxetine.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Atomoxetine.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Atomoxetine.Approved, Illicit
MidodrineAtomoxetine may increase the hypertensive activities of Midodrine.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Atomoxetine.Approved, Investigational
MinaprineMinaprine may increase the central neurotoxic activities of Atomoxetine.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Atomoxetine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Atomoxetine.Approved
MoclobemideMoclobemide may increase the central neurotoxic activities of Atomoxetine.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Atomoxetine.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Atomoxetine.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Atomoxetine.Approved, Investigational
MoxifloxacinAtomoxetine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Atomoxetine.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atomoxetine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Atomoxetine.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Atomoxetine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Atomoxetine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Atomoxetine.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Atomoxetine.Approved
NetupitantThe metabolism of Netupitant can be decreased when combined with Atomoxetine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Atomoxetine.Approved
NialamideNialamide may increase the central neurotoxic activities of Atomoxetine.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Atomoxetine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Atomoxetine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Atomoxetine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Atomoxetine.Approved
NilotinibAtomoxetine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Atomoxetine.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Atomoxetine.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Atomoxetine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Atomoxetine.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Atomoxetine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Atomoxetine.Approved, Vet Approved
NorepinephrineAtomoxetine may increase the hypertensive activities of Norepinephrine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Atomoxetine.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Atomoxetine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Atomoxetine.Approved
NylidrinAtomoxetine may increase the hypertensive activities of Nylidrin.Approved
OctamoxinOctamoxin may increase the central neurotoxic activities of Atomoxetine.Withdrawn
OfloxacinAtomoxetine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Atomoxetine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Atomoxetine.Approved
OlodaterolAtomoxetine may increase the tachycardic activities of Olodaterol.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Atomoxetine.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
OndansetronAtomoxetine may increase the QTc-prolonging activities of Ondansetron.Approved
OrciprenalineAtomoxetine may increase the hypertensive activities of Orciprenaline.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Atomoxetine.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Atomoxetine.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Atomoxetine.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Atomoxetine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineAtomoxetine may increase the hypertensive activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Atomoxetine.Approved, Vet Approved
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Atomoxetine.Approved
PaliperidoneAtomoxetine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Atomoxetine.Approved, Investigational
PanobinostatThe serum concentration of Atomoxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Atomoxetine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Atomoxetine.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Atomoxetine.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Atomoxetine.Approved
PargylinePargyline may increase the central neurotoxic activities of Atomoxetine.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Atomoxetine.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Atomoxetine.Approved
ParoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibAtomoxetine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineAtomoxetine may increase the QTc-prolonging activities of Pentamidine.Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Atomoxetine.Approved
PerflutrenAtomoxetine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Atomoxetine.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Atomoxetine.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Atomoxetine.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Atomoxetine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Atomoxetine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Atomoxetine.Withdrawn
PhenelzinePhenelzine may increase the central neurotoxic activities of Atomoxetine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Atomoxetine.Approved, Withdrawn
PheniprazinePheniprazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
PhenmetrazineAtomoxetine may increase the hypertensive activities of Phenmetrazine.Approved, Illicit
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Atomoxetine.Approved
PhenoxypropazinePhenoxypropazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Atomoxetine.Approved
PhentermineAtomoxetine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhenylephrineAtomoxetine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineAtomoxetine may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Atomoxetine can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Atomoxetine.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Atomoxetine.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Atomoxetine.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Atomoxetine.Withdrawn
PindololThe metabolism of Pindolol can be decreased when combined with Atomoxetine.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Atomoxetine.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Atomoxetine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Atomoxetine.Approved
PirbuterolAtomoxetine may increase the tachycardic activities of Pirbuterol.Approved
PirlindolePirlindole may increase the central neurotoxic activities of Atomoxetine.Approved
PivhydrazinePivhydrazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
PodofiloxThe metabolism of Podofilox can be decreased when combined with Atomoxetine.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Atomoxetine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Atomoxetine.Approved
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Atomoxetine.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Atomoxetine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Atomoxetine.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Atomoxetine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Atomoxetine.Approved, Vet Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Atomoxetine.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Atomoxetine.Approved, Vet Approved
PrimaquineAtomoxetine may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideAtomoxetine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaterolAtomoxetine may increase the hypertensive activities of Procaterol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Atomoxetine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Atomoxetine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Atomoxetine.Approved
PromazineAtomoxetine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Atomoxetine.Approved
PropafenoneThe serum concentration of Atomoxetine can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Atomoxetine.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Atomoxetine.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Atomoxetine.Approved
PseudoephedrineAtomoxetine may increase the hypertensive activities of Pseudoephedrine.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Atomoxetine.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Atomoxetine.Approved, Illicit
QuetiapineAtomoxetine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Atomoxetine.Approved
QuinidineThe serum concentration of Atomoxetine can be increased when it is combined with Quinidine.Approved
QuinineAtomoxetine may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Atomoxetine.Approved, Investigational
RacepinephrineAtomoxetine may increase the hypertensive activities of Racepinephrine.Approved
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Atomoxetine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Atomoxetine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Atomoxetine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Atomoxetine.Approved, Investigational
RasagilineRasagiline may increase the central neurotoxic activities of Atomoxetine.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Atomoxetine.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Atomoxetine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Atomoxetine.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Atomoxetine.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Atomoxetine.Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Atomoxetine.Approved
RifabutinThe metabolism of Rifabutin can be decreased when combined with Atomoxetine.Approved
RifampicinThe metabolism of Atomoxetine can be increased when combined with Rifampicin.Approved
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Atomoxetine.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Atomoxetine.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Atomoxetine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Atomoxetine.Approved, Investigational
RitodrineAtomoxetine may increase the hypertensive activities of Ritodrine.Approved
RitonavirThe serum concentration of Atomoxetine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Atomoxetine.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Atomoxetine.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Atomoxetine.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Atomoxetine.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Atomoxetine.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Atomoxetine.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Atomoxetine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Atomoxetine.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Atomoxetine.Approved, Withdrawn
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Atomoxetine.Approved
SafrazineSafrazine may increase the central neurotoxic activities of Atomoxetine.Withdrawn
SalbutamolAtomoxetine may increase the tachycardic activities of Salbutamol.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Atomoxetine.Approved
SaquinavirAtomoxetine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Atomoxetine.Approved
SelegilineSelegiline may increase the central neurotoxic activities of Atomoxetine.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Atomoxetine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Atomoxetine.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Atomoxetine.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Atomoxetine.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Atomoxetine.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Atomoxetine.Approved, Investigational
SilodosinThe metabolism of Silodosin can be decreased when combined with Atomoxetine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Atomoxetine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Atomoxetine.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Atomoxetine.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Atomoxetine.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Atomoxetine.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Atomoxetine.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Atomoxetine.Approved, Investigational
SotalolAtomoxetine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Atomoxetine.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Atomoxetine.Approved
StiripentolThe serum concentration of Atomoxetine can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Atomoxetine.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Atomoxetine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Atomoxetine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Atomoxetine.Approved
SulfisoxazoleAtomoxetine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Atomoxetine.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Atomoxetine.Approved
SynephrineAtomoxetine may increase the hypertensive activities of Synephrine.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Atomoxetine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Atomoxetine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Atomoxetine.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Atomoxetine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Atomoxetine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Atomoxetine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Atomoxetine.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Atomoxetine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Atomoxetine.Experimental
TegaserodThe metabolism of Tegaserod can be decreased when combined with Atomoxetine.Investigational, Withdrawn
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Atomoxetine.Approved
TelavancinAtomoxetine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinAtomoxetine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Atomoxetine.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Atomoxetine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Atomoxetine.Approved
TerbinafineThe serum concentration of Atomoxetine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineAtomoxetine may increase the hypertensive activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Atomoxetine.Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Atomoxetine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Atomoxetine.Approved, Investigational
TetrabenazineAtomoxetine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Atomoxetine.Approved, Vet Approved
TetryzolineAtomoxetine may increase the hypertensive activities of Tetryzoline.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Atomoxetine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Atomoxetine.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Atomoxetine.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Atomoxetine.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Atomoxetine.Approved
TiclopidineThe metabolism of Atomoxetine can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Atomoxetine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Atomoxetine.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Atomoxetine.Approved
TipranavirThe serum concentration of Atomoxetine can be increased when it is combined with Tipranavir.Approved, Investigational
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Atomoxetine.Approved, Investigational
ToloxatoneToloxatone may increase the central neurotoxic activities of Atomoxetine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Atomoxetine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Atomoxetine.Approved
TopiramateThe metabolism of Atomoxetine can be decreased when combined with Topiramate.Approved
ToremifeneAtomoxetine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Atomoxetine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Atomoxetine.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central neurotoxic activities of Atomoxetine.Experimental
TranylcypromineTranylcypromine may increase the central neurotoxic activities of Atomoxetine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Atomoxetine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Atomoxetine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Atomoxetine.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Atomoxetine.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Atomoxetine.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Atomoxetine.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Atomoxetine.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Atomoxetine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Atomoxetine.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Atomoxetine.Approved
TyramineAtomoxetine may increase the hypertensive activities of Tyramine.Investigational, Nutraceutical
UdenafilThe metabolism of Udenafil can be decreased when combined with Atomoxetine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Atomoxetine.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Atomoxetine.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Atomoxetine.Investigational, Withdrawn
VandetanibAtomoxetine may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Atomoxetine.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Atomoxetine.Approved
VemurafenibAtomoxetine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Atomoxetine.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Atomoxetine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Atomoxetine.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Atomoxetine.Investigational
VilanterolAtomoxetine may increase the tachycardic activities of Vilanterol.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Atomoxetine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Atomoxetine.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Atomoxetine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Atomoxetine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Atomoxetine.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Atomoxetine.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Atomoxetine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Atomoxetine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Atomoxetine.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Atomoxetine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Atomoxetine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Atomoxetine.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Atomoxetine.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Atomoxetine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Atomoxetine.Approved, Investigational, Withdrawn
ZiprasidoneAtomoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Atomoxetine.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Atomoxetine.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Atomoxetine.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Atomoxetine.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Atomoxetine.Approved, Investigational
Food Interactions
  • In the presence of food, the absorption rate is reduced, without the quantity absorbed being affected.
  • Take without regard to meals.
References
Synthesis Reference

Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei, “Processes for the preparation of atomoxetine hydrochloride.” U.S. Patent US20060211772, issued September 21, 2006.

US20060211772
General References
  1. Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. [PubMed:16649828 ]
  2. Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. 2006 Mar;39(2):79-80. [PubMed:16555170 ]
  3. Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005 Oct;66(10):1234-8. [PubMed:16259536 ]
  4. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. [PubMed:16113620 ]
  5. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI: Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. [PubMed:17388708 ]
  6. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  7. Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205-22. [PubMed:14717619 ]
  8. Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152. [PubMed:19785510 ]
  9. Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
External Links
ATC CodesN06BA09
AHFS Codes
  • 28:92.00
PDB EntriesNot Available
FDA labelDownload (72.8 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.964
Caco-2 permeable+0.852
P-glycoprotein substrateSubstrate0.6133
P-glycoprotein inhibitor IInhibitor0.7771
P-glycoprotein inhibitor IINon-inhibitor0.8003
Renal organic cation transporterInhibitor0.5929
CYP450 2C9 substrateNon-substrate0.7443
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6216
CYP450 1A2 substrateInhibitor0.9324
CYP450 2C9 inhibitorNon-inhibitor0.957
CYP450 2D6 inhibitorInhibitor0.9037
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8122
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7371
Ames testNon AMES toxic0.7738
CarcinogenicityNon-carcinogens0.8493
BiodegradationNot ready biodegradable0.8013
Rat acute toxicity2.5166 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7132
hERG inhibition (predictor II)Inhibitor0.7974
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
CapsuleOral10 mg
CapsuleOral100 mg
CapsuleOral100 mg/1
CapsuleOral18 mg/1
CapsuleOral18 mg
CapsuleOral25 mg
CapsuleOral25 mg/1
CapsuleOral40 mg/1
CapsuleOral40 mg
CapsuleOral60 mg
CapsuleOral60 mg/1
CapsuleOral80 mg
CapsuleOral80 mg/1
KitOral
Prices
Unit descriptionCostUnit
Strattera 80 mg capsule6.94USD capsule
Strattera 100 mg capsule6.83USD capsule
Strattera 40 mg capsule6.43USD capsule
Strattera 60 mg capsule6.43USD capsule
Strattera 18 mg capsule6.03USD capsule
Strattera 25 mg capsule5.85USD capsule
Strattera 10 mg capsule5.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2209735 No2002-10-012016-01-04Canada
US5658590 Yes1997-05-262017-05-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility27.8 mg/mLNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0039 mg/mLALOGPS
logP3.95ALOGPS
logP3.81ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity79.44 m3·mol-1ChemAxon
Polarizability29.79 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenol ether
  • Aralkylamine
  • Toluene
  • Alkyl aryl ether
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Dec;110(6):e75. [PubMed:12456942 ]
  2. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. [PubMed:12523874 ]
  3. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003 Jan 15;53(2):112-20. [PubMed:12547466 ]
  4. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40. [PubMed:12862507 ]
  5. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 Feb;24(1):30-5. [PubMed:14709944 ]
  6. Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548 ]
  7. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004 Oct;8(2):45-52. [PubMed:15801334 ]
  8. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  9. Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
  10. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. [PubMed:12431845 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
blocker
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weigt HU, Fegert JM, Boeckers TM, Fohr KJ: Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol. 2010 May;160(2):283-91. doi: 10.1111/j.1476-5381.2010.00707.x. [PubMed:20423340 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  2. Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 03:55